Jeremy Puthumana

Jeremy Puthumana

Auto-generated profile, based on publicly available information

Jeremy Puthumana

Section of Digestive Diseases, Yale School of Medicine, New Haven, Connecticut, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
JPJeremy Puthumana
Jeremy Puthumana
HTHeather Thiessen-Philbrook
Heather Thiessen-Philbrook
LXLeyuan Xu
Leyuan Xu
SCSteven G. Coca
Steven G. Coca
AGAmit X. Garg
Amit X. Garg
CPChirag R. Parikh
Chirag R. Parikh
INTRODUCTION. Acute kidney injury and chronic kidney disease (CKD) are common in hospitalized patients. To inform clinical decision making, more accurate information regarding risk of long-term progression to kidney failure is required. METHODS. We enrolled 1538 hospitalized patients in a multicenter, prospective cohort study. Monocyte chemoattractant protein 1 (MCP-1/CCL2), uromodulin (UMOD), and YKL-40 (CHI3L1) were measured in urine samples collected during outpatient follow-up at 3 months. We followed patients for a median of 4.3 years and assessed the relationship between biomarker levels and changes in estimated glomerular filtration rate (eGFR) over time and the development of a composite kidney outcome (CKD incidence, CKD progression, or end-stage renal disease). We paired these clinical studies with investigations in mouse models of renal atrophy and renal repair to further understand the molecular basis of these markers in kidney disease progression. RESULTS. Higher MCP-1 and YKL-40 levels were associated with greater eGFR decline and increased incidence of the composite renal outcome, whereas higher UMOD levels were associated with smaller eGFR declines and decreased incidence of the composite kidney outcome. A multimarker score increased prognostic accuracy and reclassification compared with traditional clinical variables alone. The mouse model of renal atrophy showed greater Ccl2 and Chi3l1 mRNA expression in infiltrating macrophages and neutrophils, respectively, and evidence of progressive renal fibrosis compared with the repair model. The repair model showed greater Umod expression in the loop of Henle and correspondingly less fibrosis. CONCLUSIONS. Biomarker levels at 3 months after hospitalization identify patients at risk for kidney disease progression. FUNDING. NIH.

20 February 2017 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
SMSherry Mansour
Sherry Mansour
JPJeremy Puthumana
Jeremy Puthumana
SCSteven G. Coca
Steven G. Coca
MGMark Gentry
Mark Gentry
CPChirag R. Parikh
Chirag R. Parikh
Fibrosis is the unifying pathway leading to chronic kidney disease. Identifying biomarkers of fibrosis may help predict disease progression. We performed a systematic review to evaluate the reliability of blood and urine biomarkers in identifying fibrosis on biopsy as well as predicting renal outcomes. Using MEDLINE and EMBASE, a two-stage search strategy was implemented. Stage I identified a library of biomarkers correlating with fibrosis on biopsy. Stage II evaluated the association between biomarkers identified in stage I, and renal outcomes. Only biomarkers with moderate positive correlation with fibrosis (r > 0.40) or acceptable area under the curve (AUC >0.65) advanced to stage II. Stage I identified 17 studies and 14 biomarkers. Five biomarkers met criteria to advance to stage II, but only three were independently associated with renal outcomes. Transforming growth factor β (TGF-β) correlated with fibrosis (r = 0.60), and was associated with 1.7–3.9 times the risk of worsening renal function in 426 patients. Monocyte chemoattractant protein-1 (MCP-1) diagnosed fibrosis with AUC of 0.66 and was associated with 2.3–11.0 times the risk of worsening renal function in 596 patients. Matrix metalloproteinase-2 (MMP-2) correlated with fibrosis (r = 0.41), and was associated with 2.5 times the risk of worsening renal function. Given the heterogeneity of the data due to diverse patient populations along with differing renal outcomes, a meta-analysis could not be conducted. Nonetheless we can conclude from the published data that TGF-β, MCP-1 and MMP-2 may identify patients at risk for renal fibrosis and hence worse renal outcomes.

17 January 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MCMaria Castañeda-Bueno
Maria Castañeda-Bueno
JAJuan Pablo Arroyo
Juan Pablo Arroyo
JZJunhui Zhang
Junhui Zhang
JPJeremy Puthumana
Jeremy Puthumana
OYOrlando Yarborough
Orlando Yarborough
RLRichard P. Lifton
Richard P. Lifton
Significance: The kinase WNK4 (with-no-lysine kinase 4) is an important regulator of the Na-Cl cotransporter (NCC) in the renal distal convoluted tubule (DCT). Volume depletion induces angiotensin II, activating PKC, which prevents WNK4 degradation by phosphorylating the KLHL3/CUL3 ubiquitin ligase. We now show that PKC also directly phosphorylates WNK4 at multiple sites in cell culture. Phosphorylation of two of these sites, S64 and S1196, promotes increased WNK4 kinase activity by increasing autophosphorylation of the WNK4 T-loop at S332. Volume depletion also induces phosphorylation of WNK4-S64 in the DCT in vivo, promoting NCC activity. These findings provide insights into the mechanisms regulating activity of NCC and the promotion of renal Na-Cl reabsorption without concomitant K+secretion in volume depletion.

11 October 2021 in BMJ Evidence-Based Medicine
Verified
Journal Article
Closed access
PDF file
JPJeremy Puthumana
Jeremy Puthumana
AEAlexander C Egilman
Alexander C Egilman
RRReshma Ramachandran
Reshma Ramachandran
NNNida Naushad
Nida Naushad
NSNilay Shah
Nilay Shah
JRJoseph Ross
Joseph Ross
Although many laud these novel gene therapies as clinically transformative, there is growing concern about the high cost of these products, with list prices for one-time infusions ranging from $373 000 to as much as $2.1 million.6 In addition, gene therapies have been associated with serious safety risks including life-threatening immune responses and insertional mutagenesis-induced malignancies.7 As more gene therapies begin to enter the market, understanding the FDA’s past practices and standards in their review and approval of these products will help inform future regulatory decision-making, particularly upcoming approvals through the RMAT pathway, reimbursement decisions of payors, and the clinical …

23 September 2019 in medRxiv
Verified
Preprint
Open access
PDF file
AZAudrey D. Zhang
Audrey D. Zhang
JPJeremy Puthumana
Jeremy Puthumana
NDNicholas S. Downing
Nicholas S. Downing
NSNilay D. Shah
Nilay D. Shah
HKHarlan M Krumholz
Harlan M Krumholz
JRJoseph S. Ross
Joseph S. Ross
Objective: To evaluate whether characteristics of pivotal efficacy trials supporting US Food and Drug Administration (FDA) approval of novel therapeutic agents have changed over the past three decades. Design: Cross-sectional study. Setting and population: Publicly available data on novel therapeutics approved by the FDA between 1995-1997, 2005-2007, and 2015-2017. Main outcome measures: Use of randomization, blinding, types of comparators and primary endpoints, number of treated patients, and trial duration in pivotal trials supporting novel therapeutic approval, both individually and aggregated by each indication approval. Analyses were repeated stratifying by use of orphan designation and use of special regulatory programs. Results: There were 273 novel therapeutics approved by the FDA in these 3 periods (107 in 1995-1997, 57 in 2005-2007, 109 in 2015-2017), representing 339 indications (157, 64, and 118, respectively). Overall, the proportion of indication approvals supported by at least 2 pivotal trials decreased (80.6% in 1995-1997, 60.3% in 2005-2007, 52.8% in 2015-2017; p<0.001). The proportion supported by only single-arm pivotal trials increased (4.0% in 1995-1997, 12.7% in 2005-2007, 17.0% in 2015-2017; p=0.001), as did the proportion supported by at least one pivotal trial of 6 months’ duration (25.8% in 1995-1997, 34.9% in 2005-2007, 46.2% in 2015-2017; p=0.001). When stratified by use of special regulatory programs, pivotal trial characteristics changed over time in divergent ways, both individually and when aggregated by indication approvals. Conclusion: More recent FDA approvals of novel therapeutics were based on fewer pivotal trials, with less rigorous designs but longer trial durations. These findings reinforce the importance of FDA’s strategy for requiring ongoing evaluation of therapeutic safety and efficacy after approval. What is already known on this topic: - Pivotal trial characteristics supporting US Food and Drug Administration approval of novel therapeutic agents vary widely across therapeutic characteristics. - A growing number of approvals make use of special regulatory programs that expedite the development and review of potentially transformative drugs, such as Fast Track, Priority Review, Accelerated Approval, and Breakthrough Designation. - Special regulatory programs often offer more flexible requirements for approval, such as requiring only a single pivotal trial or trials using surrogate endpoints. What this study adds: - Over the past three decades, the characteristics of the aggregate pivotal trials supporting new drug approvals has changed, with more recent approvals requiring fewer trials of less rigorous design. - Differences in pivotal trial characteristics over time persist after accounting for the increasing use of special regulatory programs. - Divergent patterns are observed among approvals making use of special regulatory programs, for which more recent approvals have required fewer trials of less rigorous design, as compared to approvals using the standard pathway, for which more recent approvals have required trials of more rigorous design.

27 March 2026 in Liver Transplantation
Verified
Journal Article
Closed access
JPJeremy Puthumana
Jeremy Puthumana
JBJustin M. Belcher
Justin M. Belcher
GGGuadalupe Garcia-Tsao
Guadalupe Garcia-Tsao
JIJoachim H. Ix
Joachim H. Ix
WOWassim Obeid
Wassim Obeid
CPChirag R. Parikh
Chirag R. Parikh
Background: Acute kidney injury (AKI) is a frequent and severe complication in patients with cirrhosis. Identifying patients at high risk for AKI progression and in-hospital complications could enable timely targeted interventions. Given the central role of inflammation in AKI and cirrhosis, we investigated whether inflammatory biomarkers could provide prognostic insights. Methods: In this multicenter, prospective cohort study, we enrolled 188 patients with cirrhosis and AKI from four tertiary care centers. Urine and plasma samples were analyzed for four biomarkers: urine monocyte chemoattractant protein-1 (MCP-1), urine YKL-40, and plasma tumor necrosis factor receptors 1 and 2 (TNFR-1, TNFR-2). Biomarkers were assessed for their associations with AKI progression, mortality, and in-hospital complications using multivariate analyses adjusted for demographics, baseline kidney function, and MELD score. Results: Urine MCP-1, plasma TNFR-1, and plasma TNFR-2 were each associated with increased odds of AKI progression and mortality: urine MCP-1 had odds ratio (OR) 2.35 (95% CI,1.26–5.65), plasma TNFR-1 OR 6.90 (95% CI,2.45–25.50), and plasma TNFR-2 OR 2.69 (95% CI,1.34–6.17) per standard deviation (SD) higher biomarker level. Plasma TNFR-1 had the strongest associations with in-hospital complications. Each SD higher plasma TNFR-1 was associated with developing hepatic encephalopathy (OR 2.53; 95% CI,1.37–5.06), developing spontaneous bacterial peritonitis (OR 2.20; 95% CI,1.14–4.47), variceal bleeding during admission (OR 3.47; 95% CI,1.05-14.46), and requiring dialysis (OR 2.81; 95% CI,1.39–6.23). Discussion: Inflammatory biomarkers effectively identify high-risk patients with AKI and cirrhosis. Incorporating these biomarkers into clinical decision-making has the potential to guide treatment. Export